New Carotid PCI All-in-One System

Carotid stenting is equivalent to carotid endarterectomy in terms of major adverse events (death, AMI, and stroke). However, it entails higher risk of minor stroke due to micro-particle embolization, when conventional thromboembolic protection devices won’t capture them. 

Neuroguard IEP System integrates a 40-micron distal thromboembolic filter, a post-dilation balloon, and a stent, reducing catheter exchange and improving thromboembolic protection. 

The PERFORMANCE II was a prospective, multicenter, single arm study including 305 patients with significant carotid stenosis and high risk of carotid endarterectomy. 

Primary end point was a composite of death, any stroke or myocardial infarction within 30 days. 

Patients mean age was 69.6 ± 7.5 years, 65.9% were men, and 20% were symptomatic. Hypertension prevalence was 93%, and diabetes 43%. Main risk factors included hypertension, stroke or TIA in 21% of cases, and a history of endarterectomy in 10%.

25% of patients presented high risk anatomy for this procedure and nearly half had significant comorbidities. The right carotid was the most treated artery (51%), with post endarterectomy 7% restenosis rate and severe calcification in 34% of cases. 

Read also: Is Angioplasty Always Necessary after TAVR?

Primary end point was seen in 2.3% of cases, with 0.3% mortality, 1.3% stroke and 0.7% MI. At 12 months there were no neurological deaths, stroke or major stent thrombosis. Target lesion revascularization (TLR) rate was 1.1%, and incidence of any stroke 1.8%.

A subgroup analysis revealed that asymptomatic patients had a stroke/death rate of 1.2% at 30 days, vs symptomatic patients (p=0.175). stroke rate at 30 days was similar between patients under 70 or more (1.8%; p=0.633), with no significant differences in sex. (p=1.000).

Conclusion

Major adverse events rate resulted extremely low, showing its safety, efficacy and durability in high risk patients. 

Original Title: A Prospective Multicenter Investigation of a Novel Carotid Stent System: The PERFORMANCE II Trial.

Reference: William A. Gray et al. JACC: Cardiovascular Interventions, Volumen 18, 367–376, 2025.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Carlos Fava
Dr. Carlos Fava
Member of the Editorial Board of solaci.org

More articles by this author

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...

IVUS-Guided vs. Angiography-Guided Drug-Coated Balloon Angioplasty in the Treatment of Femoropopliteal Lesions

Angiography has traditionally been the primary imaging technique for endovascular therapy guidance in patients with peripheral artery disease. However, as it only provides two-dimensional...

PERFORMANCE II Trial: Safety and Efficacy of the New NeuroGuard Carotid Stent System

The percutaneous treatment of carotid artery disease through stenting (CAS) for the prevention of cerebrovascular disease has proven to be an effective alternative compared...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...